NASDAQ | ETF
Top 20 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| AMGN | Amgen Inc | Healthcare | Drug Manufacturers - General | 8.64% |
| VRTX | Vertex Pharmaceuticals Inc | Healthcare | Biotechnology | 8.28% |
| REGN | Regeneron Pharmaceuticals Inc | Healthcare | Biotechnology | 8.01% |
| GILD | Gilead Sciences Inc | Healthcare | Drug Manufacturers - General | 7.95% |
| IQV | IQVIA Holdings Inc | Healthcare | Diagnostics & Research | 4.5% |
| MRNA | Moderna Inc | Healthcare | Biotechnology | 3.86% |
| BIIB | Biogen Inc | Healthcare | Drug Manufacturers - General | 3.21% |
| MTD | Mettler-Toledo International Inc | Healthcare | Diagnostics & Research | 2.79% |
| ILMN | Illumina Inc | Healthcare | Diagnostics & Research | 2.06% |
| ARGX | argenx NV ADR | Healthcare | Biotechnology | 2% |
| WAT | Waters Corporation | Healthcare | Diagnostics & Research | 1.96% |
| BNTX | BioNTech SE | Healthcare | Biotechnology | 1.92% |
| ALNY | Alnylam Pharmaceuticals Inc | Healthcare | Biotechnology | 1.92% |
| GMAB | Genmab AS | Healthcare | Biotechnology | 1.69% |
| BMRN | Biomarin Pharmaceutical Inc | Healthcare | Biotechnology | 1.6% |
| NBIX | Neurocrine Biosciences Inc | Healthcare | Drug Manufacturers - Specialty & Generic | 1.41% |
| BGNE | BeiGene Ltd | Healthcare | Biotechnology | 1.32% |
| CRL | Charles River Laboratories | Healthcare | Diagnostics & Research | 1.23% |
| INCY | Incyte Corporation | Healthcare | Biotechnology | 1.22% |
| SRPT | Sarepta Therapeutics Inc | Healthcare | Biotechnology | 1.21% |
The fund generally will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.